Sunshine Biopharma Inc
OTC:SBFM
Intrinsic Value
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. [ Read More ]
The intrinsic value of one
SBFM
stock under the Base Case scenario is
23.4186
USD.
Compared to the current market price of 0.8602 USD,
Sunshine Biopharma Inc
is
Undervalued by 96%.
Sunshine Biopharma Inc's market capitalization is 85.5m USD.
SBFM stock price is 0.8602 USD.
SBFM stock price (0.8602 USD) is 96% less than its Intrinsic Value (23.4186 USD).
SBFM stock price (0.8602 USD) is 98% less than its Relative Value (43.025 USD). Open Relative Valuation
SBFM has upside potential of 256% compared to the average analyst price target.
Open Wall St Estimates
SBFM's Revenue has grown by an exceptional 454% over the past 12 months.
SBFM's ROE (Return on Equity) has significantly decreased in the last 3 years from 992% to -21%.
SBFM's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 2 586% to -80%.
SBFM has positive Gross Profit for the last twelve months.
SBFM has negative Operating Income for the last twelve months.
SBFM has negative Net Income for the last twelve months.
SBFM's ROE (Return on Equity) for the past 12 months is negative and is equal to -21%.
SBFM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -80%.
SBFM has negative Free Cash Flow for the last twelve months.
SBFM's Revenue has been growing by an exceptional 601% per year for the last 3 years.
SBFM has very high three-year average ROE (Return on Equity): 548%. The company is very efficient at transforming stockholders' equity into net income.
SBFM has negative three-year average ROIC (Return on Invested Capital): -734%. The company is not efficient at using invested capital to generate operating income.
SBFM's short-term assets (25m USD) exceed its short-term liabilties (6m USD).
SBFM's long-term assets (27m USD) exceed its long-term liabilties (6m USD).
SBFM's D/E (Debt to Equity) is very low and is equal to 0.
SBFM's Altman Z-Score is very high and is equal to 261.03.
Fundamental Analysis
Sunshine Biopharma Inc
Balance Sheet Decomposition
Sunshine Biopharma Inc
| Current Assets | 24.9m |
| Cash & Short-Term Investments | 16.3m |
| Receivables | 2.6m |
| Other Current Assets | 6m |
| Non-Current Assets | 2.5m |
| PP&E | 1m |
| Intangibles | 1.4m |
| Other Non-Current Assets | -10 |
| Current Liabilities | 5.6m |
| Accounts Payable | 2.6m |
| Accrued Liabilities | 118.7k |
| Other Current Liabilities | 2.8m |
| Non-Current Liabilities | 587.8k |
| Other Non-Current Liabilities | 587.8k |
Earnings Waterfall
Sunshine Biopharma Inc
|
Revenue
|
24.1m
USD
|
|
Cost of Revenue
|
-15.8m
USD
|
|
Gross Profit
|
8.3m
USD
|
|
Operating Expenses
|
-13.1m
USD
|
|
Operating Income
|
-4.8m
USD
|
|
Other Expenses
|
279.3k
USD
|
|
Net Income
|
-4.5m
USD
|
Free Cash Flow Analysis
Sunshine Biopharma Inc
SBFM Profitability Score
Profitability Due Diligence
Sunshine Biopharma Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Sunshine Biopharma Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
SBFM Solvency Score
Solvency Due Diligence
Sunshine Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Sunshine Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SBFM Price Targets Summary
Sunshine Biopharma Inc
According to Wall Street analysts, the average 1-year price target for
SBFM
is 3.06 USD
with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
Ownership
SBFM Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SBFM Price
Sunshine Biopharma Inc
| Average Annual Return | 56% |
| Standard Deviation of Annual Returns | 203.1% |
| Max Drawdown | -100% |
| Market Capitalization | 85.5m USD |
| Shares Outstanding | 99 450 000 |
| Percentage of Shares Shorted | 7.32% |
Company Profile
Sunshine Biopharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
You don't have any saved screeners yet
